# The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

> **NCT04433845** · PHASE2 · UNKNOWN · sponsor: **Sheppard Pratt Health System** · enrollment: 15 (actual)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT04433845
- **Lead sponsor:** Sheppard Pratt Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-01-15
- **Final completion:** 2023-04-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433845, "The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04433845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*